AAAhmed Moussa Amer

Ahmed Moussa Amer

*This is an algorithmically generated author record based on publicly available information.

Ahmed Moussa Amer has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    IMPACT OF GLYCINE BETAINE ON COOLED CAMEL SEMEN QUALITY AND FERTILITY RATE .

    by Ahmed Moussa Amer, Alas Syd Zeidan, Dalia El-Tahan, Liza Abdel-Rafaa

    The purpose of the current investigation was to determine the impact of adding various oncentrations of glycine betaine (GB) to spermatozoa from camels that had been extended with a lactose-yolk-citrate (LYC) extender and kept at 5 OC for three days. Using an artificial vagina, semen was extracted from five camels and prolonged with LYC extender free-GB medium (first medium), or at 100 mM, 200 mM, or 300 mM GB for second, third, and fourth media, respectively. The ultimate sperm concentration was 100x106 sperms per ml, and she camels that were inseminated using extended semen from first, second, third and fourth groups were determined after 45 days. The percentage of motile camel spermatozoa extended with LYC extender added to 100 or 200 mM GB were considerably greater (P 0.05) compared to 300 mM GB or free-GB media, according to the results. However, upon storage time, the proportion of dead, aberrant, damaged acrosomes and chromatin as well as the activity of the AST and ALT enzymes were considerably (P 0.05) lower than before. With or without the GB medium, the quality of the camel semen considerably (P 0.05) decreased when storage time was extended. Additionally, the first, second, third, and fourth media's respective fertility rates for one day of the artificially inseminated dromedary she-camels were 31.57, 52.63, 47.61, and 26.31%. In conclusion, GB addition to the cooled camel spermatozoa at 100 or 200 mM, while being stored at 5 OC, was found to enrich the camel sperm quality and fertility rates.

  • Pancreatic Ductal Adenocarcinoma: Interface Enhancement Gradient Measured on Dual-Energy CT Images Improves Prognostic Evaluation

    by Ahmed M. Amer, Yufeng Li, David Summerlin, Constantine M. Burgan, Michelle M. McNamara, Andrew D. Smith, Desiree E. Morgan

    Patients with pancreatic ductal adenocarcinoma tumors that demonstrate high tumor-host enhancement gradient (delta) have poorer clinical outcomes, measured by overall survival and distant metastasi... Purpose To investigate the prognostic value of differential enhancement on baseline dual-energy CT images in patients with treatment-naive pancreatic ductal adenocarcinoma (PDAC), with a focus on t...


  • Open Access

    Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer

    by Chad Tang, Brian Hobbs, Ahmed Amer, Xiao Li, Carmen Behrens, Jaime Rodriguez Canales, Edwin Parra Cuentas, Pamela Villalobos, David Fried, Joe Y. Chang, et al.

    With increasing use of immunotherapy agents, pretreatment strategies for identifying responders and non-responders is useful for appropriate treatment assignment. We hypothesize that the local immune micro-environment of NSCLC is associated with patient outcomes and that these local immune features exhibit distinct radiologic characteristics discernible by quantitative imaging metrics. We assembled two cohorts of NSCLC patients treated with definitive surgical resection and extracted quantitative parameters from pretreatment CT imaging. The excised primary tumors were then quantified for percent tumor PDL1 expression and density of tumor-infiltrating lymphocyte (via CD3 count) utilizing immunohistochemistry and automated cell counting. Associating these pretreatment radiomics parameters with tumor immune parameters, we developed an immune pathology-informed model (IPIM) that separated patients into 4 clusters (designated A-D) utilizing 4 radiomics features. The IPIM designation was significantly associated with overall survival in both training (5 year OS: 61%, 41%, 50%, and 91%, for clusters A-D, respectively, P = 0.04) and validation (5 year OS: 55%, 72%, 75%, and 86%, for clusters A-D, respectively, P = 0.002) cohorts and immune pathology (all P < 0.05). Specifically, we identified a favorable outcome group characterized by low CT intensity and high heterogeneity that exhibited low PDL1 and high CD3 infiltration, suggestive of a favorable immune activated state. We have developed a NSCLC radiomics signature based on the immune micro-environment and patient outcomes. This manuscript demonstrates model creation and validation in independent cohorts.


  • Open Access

    Imaging‐based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

    by Ahmed M. Amer, Mohamed Zaid, Baishali Chaudhury, Dalia Elganainy, Yeonju Lee, Christopher T. Wilke, Jordan Cloyd, Huamin Wang, Anirban Maitra, Robert A. Wolff, et al.

    BACKGROUND: The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response.METHODS: Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol‐based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1‐3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform.RESULTS: In cohort 1, type I responders had a greater probability of achieving a complete or near‐complete pathologic response (21% vs 0%; P = .01). For cohorts 1, 2, and 3, type I responders had significantly longer disease‐free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19‐9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3).CONCLUSIONS: Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701‐9. © 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.


  • Open Access

    Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib

    by Jan A. Burger, Kelvin W. Li, Michael J. Keating, Mariela Sivina, Ahmed M. Amer, Naveen Garg, Alessandra Ferrajoli, Xuelin Huang, Hagop Kantarjian, William G. Wierda, et al.

    BACKGROUND. Ibrutinib is an effective targeted therapy for patients with chronic lymphocytic leukemia (CLL) that inhibits Bruton’s tyrosine kinase (BTK), a kinase involved in B cell receptor signaling. METHODS. We used stable isotopic labeling with deuterated water ( 2 H 2 O) to measure directly the effects of ibrutinib on leukemia cell proliferation and death in 30 patients with CLL. RESULTS. The measured average CLL cell proliferation (“birth”) rate before ibrutinib therapy was 0.39% of the clone per day (range 0.17%–1.04%); this decreased to 0.05% per day (range 0%–0.36%) with treatment. Death rates of blood CLL cells increased from 0.18% per day (average, range 0%–0.7%) prior to treatment to 1.5% per day (range 0%–3.0%) during ibrutinib therapy, and they were even higher in tissue compartments. CONCLUSIONS. This study provides the first direct in vivo measurements to our knowledge of ibrutinib’s antileukemia actions, demonstrating profound and immediate inhibition of CLL cell proliferation and promotion of high rates of CLL cell death. TRIAL REGISTRATION. This trial was registered at clinicaltrials.gov (NCT01752426). FUNDING. This study was supported by a Cancer Center Support Grant (National Cancer Institute grant P30 CA016672), an NIH grant (CA081554) from the National Cancer Institute, MD Anderson’s Moon Shots Program in CLL, and Pharmacyclics, an AbbVie company.